CTSO · Cytosorbents Corp
$0.40
+0.04 (+10.38%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$25.13M
Shares
62.84M
Cytosorbents Corp Earnings Call Transcripts
Every quarterly earnings call for Cytosorbents Corp (CTSO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼16.9%
$8.11M
−$12.20M
'22 Q3
22-11-03
▼12.9%
$9.39M
−$766,126
'22 Q4
23-03-09
▲8.7%
$9.45M
−$7.33M
'23 Q1
23-05-02
▲10.9%
$9.42M
−$6.15M
'23 Q2
23-08-02
▲8.6%
$8.81M
−$9.19M
'23 Q3
23-11-09
▼7.7%
$8.67M
−$6.57M
'23 Q4
24-03-15
▼4.9%
$8.99M
−$6.09M
'24 Q1
24-05-09
▼6.1%
$8.84M
−$4.29M
'24 Q2
24-08-14
▼2.2%
$8.61M
−$2.77M
'24 Q3
24-10-01
▲5.6%
$9.15M
−$7.57M
'24 Q4
25-03-04
▼2.9%
$8.73M
−$1.48M
'25 Q1
25-05-14
▲8.8%
$9.62M
$1.95M
'25 Q2
25-06-30
▲10.1%
$9.48M
−$3.17M
'25 Q3
25-11-13
▲0.9%
$9.23M
−$5.50M
'25 Q4
26-03-25
▲1.6%
$8.86M
−$5.13M
'26 Q1
26-05-13
LATEST
▲0.2%
$9.63M
−$4.42M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Cytosorbents Corp Q2 FY2026 Earnings Call
Revenue
$9.63M
▲ 0.2% YoY Diluted EPS
$-0.07
▼ 333.3% YoY Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Cytosorbents Corp Q1 FY2026 Earnings Call
Positive tone
DrugSorb-ATR U.S. regulatory pathway
Core CytoSorb international commercial performance
Geopolitical disruption in the Middle East
Revenue
$8.86M
▲ 1.6% YoY Diluted EPS
$-0.08
Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Cytosorbents Corp Q4 FY2025 Earnings Call
Positive tone
DrugSorb-ATR FDA resubmission
Germany restructuring and sales recovery
Path to operating cash flow break-even
Revenue
$9.23M*
▲ 0.9% YoY Gross margin
73.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Cytosorbents Corp Q3 FY2025 Earnings Call
Positive tone
DrugSorb-ATR FDA Pathway
Germany Sales Restructuring
Cash Flow Breakeven Path
Revenue
$9.48M
▲ 10.1% YoY Diluted EPS
$-0.05
Gross margin
70.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Cytosorbents Corp Q2 FY2025 Earnings Call
Positive tone
CytoSorb product and sepsis clinical evidence
DrugSorb ATR regulatory process
Gross margin performance
Revenue
$9.62M
▲ 8.8% YoY Diluted EPS
$0.03
Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Cytosorbents Corp Q1 FY2025 Earnings Call
Positive tone
DrugSorb-ATR regulatory status
Core CytoSorb business performance
Germany sales reorganization
Revenue
$8.73M
▼ 2.9% YoY Diluted EPS
$-0.02
Gross margin
71.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Cytosorbents Corp Q4 FY2024 Earnings Call
Revenue
$9.15M*
▲ 5.6% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-01
Cytosorbents Corp Q3 FY2024 Earnings Call
Positive tone
DrugSorb ATR U.S. and Canada regulatory pathway
CytoSorb international core business growth
PuriFi pump as enabling technology
Revenue
$8.61M
▼ 2.2% YoY Diluted EPS
$-0.05
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Cytosorbents Corp Q2 FY2024 Earnings Call
Positive tone
DrugSorb-ATR Regulatory Submission
Revenue and Product Sales Growth
Taiwan Market Opportunity
Revenue
$8.84M
▼ 6.1% YoY Diluted EPS
$-0.08
Gross margin
73.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Cytosorbents Corp Q1 FY2024 Earnings Call
Positive tone
DrugSorb-ATR regulatory submissions
Clinical evidence and new indications
Product sales growth and post-COVID recovery
Revenue
$8.99M
▼ 4.9% YoY Diluted EPS
$-0.11
Gross margin
76.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-15
Cytosorbents Corp Q4 FY2023 Earnings Call
Balanced tone
STAR-T trial and regulatory pathway for DrugSorb-ATR
India distribution partnership with Eris Lifesciences/ARRIS
Sales performance and growth across regions
Revenue
$8.67M
▼ 7.7% YoY Diluted EPS
$-0.12
Gross margin
61.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Cytosorbents Corp Q3 FY2023 Earnings Call
Revenue
$8.81M
▲ 8.6% YoY Diluted EPS
$-0.21
Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Cytosorbents Corp Q2 FY2023 Earnings Call
Revenue
$9.42M
▲ 10.9% YoY Diluted EPS
$-0.15
Gross margin
63.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Cytosorbents Corp Q1 FY2023 Earnings Call
Revenue
$9.45M
▲ 8.7% YoY Diluted EPS
$-0.17
Gross margin
57.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Cytosorbents Corp Q4 FY2022 Earnings Call
Revenue
$9.39M
▼ 12.9% YoY Diluted EPS
$-0.02
Gross margin
61.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytosorbents Corp Q3 FY2022 Earnings Call
Revenue
$8.11M
▼ 16.9% YoY Diluted EPS
$-0.28
Gross margin
44.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Cytosorbents Corp Q2 FY2022 Earnings Call
Revenue
$8.50M
▼ 29.3% YoY Diluted EPS
$-0.25
Gross margin
58.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytosorbents Corp Q1 FY2022 Earnings Call
Revenue
$8.69M
▼ 18% YoY Diluted EPS
$-0.21
Gross margin
73.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Cytosorbents Corp Q4 FY2021 Earnings Call
Revenue
$10.78M
▼ 9.8% YoY Diluted EPS
$-0.25
Gross margin
71.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-13
Cytosorbents Corp Q3 FY2021 Earnings Call
Revenue
$9.76M
▼ 7.5% YoY Diluted EPS
$-0.15
Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Cytosorbents Corp Q2 FY2021 Earnings Call
Revenue
$12.02M
▲ 22.8% YoY Diluted EPS
$-0.11
Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Cytosorbents Corp Q1 FY2021 Earnings Call
Revenue
$10.60M
▲ 21.7% YoY Diluted EPS
$-0.10
Gross margin
74.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Cytosorbents Corp Q4 FY2020 Earnings Call
Revenue
$11.96M
▲ 60.9% YoY Diluted EPS
$0.00
Gross margin
78.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Cytosorbents Corp Q3 FY2020 Earnings Call
Revenue
$10.55M
▲ 73% YoY Diluted EPS
$-0.02
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Cytosorbents Corp Q2 FY2020 Earnings Call
Revenue
$9.79M
▲ 57.2% YoY Diluted EPS
$-0.08
Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Cytosorbents Corp Q1 FY2020 Earnings Call
Revenue
$8.71M
▲ 67.7% YoY Diluted EPS
$-0.10
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Cytosorbents Corp Q4 FY2019 Earnings Call
Revenue
$7.43M
▲ 22.2% YoY Diluted EPS
$-0.13
Gross margin
71.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1175151
CUSIP
23283X206
13F (30d)
50 filings
50 filers
Visit website
Investor relations